The Simultaneous Estimation of the Influx and Efflux Blood-Brain Barrier Permeabilities of Gabapentin Using a Microdialysis-Pharmacokinetic Approach

Pharmaceutical Research

Volumn 13, Issue 3, 1996, Pages 398-403

  Wang, Yanfeng ^a   Welty, Devin F ^b  

^a Sandoz Pharma Ltd   (Switzerland)

^b PFIZER INC   (United States)

Author keywords

Blood brain barrier; Clearance; Gabapentin; Microdialysis; Permeability; Rat; Retrodialysis; Transport

Indexed keywords

GABAPENTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; BRAIN TISSUE; DRUG PENETRATION; DRUG TRANSPORT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETIC ACIDS; AMINES; ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; CYCLOHEXANECARBOXYLIC ACIDS; DIALYSIS; GAMMA-AMINOBUTYRIC ACID; MALE; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS;

EID: 0029876793     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016092525901     Document Type: Article

References (25)

1. J. Kehr. A survey on quantitative microdialysis: theoretical models and practical implications. J. Neurosci. Methods 48:251-261 (1993).
2. Y. Wang, S. L. Wong, and R. J. Sawchuk. Microdialysis calibration using retrodialysis and zero-net flux: Application to a study of the distribution of zidovudine to rabbit CSF and thalamus. Pharm. Res. 10, 1411-1419 (1993).
3. Y. Wang and R. J. Sawchuk. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J. Pharm. Sci. 84:871-876 (1995).
4. Y. Takasato, S. I. Rapoport, Q. R. Smith. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 16:H484-H493 (1984).
5. H. Benveniste and P. C. Huttemeier. Microdialysis: Theory and application. Progress in Neurobiology. 35:195-215 (1990).
6. D. F. Welty, G. P. Schielke, M. G. Vartanian, C. P. Taylor. Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Res. 16:175-181 (1993).
7. L. L. Radulovic, D. Turck, A. Von Hodenberg, K.-O. Vollmer, W. P. McNally, P. D. Dehart, B. J. Hanson, H. N. Bockbrader, and T. Chang. Disposition of gabapentin (Neurontin) in mice, rats, dogs, and monkeys. Drug Met. Disp. 23:441-448 (1995).
8. Rosenberg, G. A. Brain Fluids and Metabolism, Oxford University Press, New York, NY, 1990, pp. 15-53.
9. B. K. Malhotra, M. Lemaire, and R. J. Sawchuk. Investigation of the distribution of EAB 515 to cortical ECF and CSF in freely moving rats utilizing microdialysis. Pharm. Res. 11:1223-1232 (1994).
10. C. I. Larsson. The use of an 'internal standard' for control of recovery in microdialysis. Life Sci. 49:73-78 (1991).
11. D. Scheller and J. Kolb. The internal reference technique in microdialysis: A practical approach to monitoring dialysis efficiency and calculating tissue concentration from dialysate samples. J. Neurosci. Methods 40:31-48 (1991).
12. E. Ben-Menachem, L. I. Persson and T. Hedner. Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. Epilepsy Res. 11:45-49 (1992).
13. M. Bradbury. The Concept of a Blood-Brain Barrier, John Wiley & Sons, New York, 1979, pp 120.
14. D. O. Cooney. Biomedical Engineering Principles, Marcel Dekker, Inc., New York, 1976.
15. K. H. Dykstra, A. Arya, D. M. Arriola, P. M. Bungay, P. F. Morrison, and R. L. Dedrick. Microdialysis study of zidovudine (AZT) transport in rat brain. J. Pharmacol. Exp. Therap. 267:1227-1236 (1993).
16. W. M. Pardridge. Brain drug delivery and blood-brain barrier transport. Drug Delivery. 1:83-101 (1993).
17. T.-Z. Su, E. Lunney, G. Campbell, and D. L. Oxender. Transport of gabapentin, a γ-amino acid drug, by system L α-amino acid transporters: a comparative study in astrocytes, synaptosomes and CHO cells. J. Neurochem. 64:2125-2131 (1995).
18. H. F. Cserr and C. S. Patlak. Secretion and bulk flow of interstitial fluid. In M. W. B. Bradbury (eds.), Physiology and Pharmacology of the Blood-Brain Barrier, Springer-Verlag, New York, NY, 1993, pp. 246-253.
19. M. B. Segal and B. V. Zlokovic. The Blood-Brain Barrier, Amino Acids and Peptides. Kluwer Academic Publishers, Boston, 1990, pp 37.
20. G. D. Bartoszyk, N. Meyerson, W. Reimann, G. Satzinger., A. Von Hodenberg. In: Current Problems in Epilepsy, vol. 4, Anticonvulsant Drugs, Eds. Meldrum B.S., Porter R. J., London, John Libbey 1986, 147-163.
21. B. H. Stewart, A. R. Kugler, P. R. Thompson, and H. N. Bockbrader. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. 10:276-281 (1993).
22. H. Davson, B. Zlokovic, L. Rakic, and M. B. Segal. An Introduction to the Blood-Brain Barrier. CRC Press, Inc., Ann Arbor, 1993, p. 174.
23. D. C. Markovitz and J. D. Fernstrom. Diet and uptake of aldomet by the brain: competition with natural large neutral amino acids. Science 197:1014-1015(1977).
24. A. L. Betz and G. W. Goldstein. Polarity of the blood-brain barrier: neutral amino acid transport into isolated brain capillaries. Science, 202:225-226 (1978).
25. R. J. Thurlow, J. P. Brown, N. S. Gee, D. R. Hill, and G. N. Woodruff. [3H]gabapentin may label a system-L-like neutral amino acid carrier in brain. Eur. J. Pharmacol., Mol. Pharmacol. 247:341-345 (1993).